Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Net income | -$1.56M | -$2.10M | -$21.5M | -$9.38M | -$8.69M | -$8.96M | -$15.8M |
| EPS (diluted) | -$0.52 | -$0.70 | -$0.01 | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.30M | -$1.34M | -$5.72M | -$8.48M | -$7.86M | -$7.86M | -$13.5M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $324K | $7.48M | $2.86M | $2.40M | $3.62M | $3.82M |
| Total assets | — | $1.38M | $9.36M | $14.5M | $12.2M | $15.7M | $20.4M |
| Total liabilities | — | $7.99M | $8.70M | $7.05M | $6.51M | $6.50M | $7.27M |
| Shareholders' equity | -$4.51M | -$6.61M | $657K | $7.41M | $5.66M | $9.20M | $13.1M |
| Retained earnings | — | -$6.61M | -$28.1M | -$37.5M | -$46.2M | -$55.2M | -$71.0M |
| Shares (wtd avg diluted) | 1.20B | 1.20B | 3.35B | 404K | 987K | 8.95M | 52.4M |
Every figure is extracted from Quoin Pharmaceuticals, Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.